American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

By L. Harris, H. Fritsche, R. Mennel, Larry Norton, P. Ravdin, S. Taube, M. Somerfield, D. Hayes, R. Bast. Journal of Clinical Oncology, 2007

1,250 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/431b703cab72c6a6c29015ef8f0dc67c5af17f67

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. K. Pantel
2. Ruud H. Brakenhoff
3. B. Brandt
4. C. Alix‐Panabières

In Oncology

1. K. Pantel
2. Ruud H. Brakenhoff
3. B. Brandt
4. C. Alix‐Panabières
5. J. Massagué

Citations in the corpus

• Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis (2018, background): “29, urokinase plasminogen activator (UPA), plasminogen activator inhibitor 1 (PAI), and certain multiparameter gene expression assays.(366) Among these biomarkers HER2 has attracted much attention as a possible prognostic marker.”
• Detection, clinical relevance and specific biological properties of disseminating tumour cells (2008, background): “In 2007 CTCs and DTCs in BM were cited for the first time in the recommendations of the American Society of Clinical Oncology (ASCO) on tumour marker”